In vitro activity of moxifloxacin(BAY 12-8039) against respiratory tract pathogens from six Latin-American countries.
The in vitro antibacterial activity of moxifloxacin (BAY 12-8039) was evaluated against 636 isolates of respiratory tract pathogens. The isolates were collected from July 1997 to August 1998 in the frame of a multinational Latin American study. E-test strips calibrated to read moxifloxacin MIC ranges from 0.002 to 32 microg/ml were used in susceptibility testing. Weekly quality control tests in each laboratory ensured reproducibility. Laboratories from Argentina, Brazil, Chile, Colombia, Mexico and Uruguay participated. MIC(90) for moxifloxacin were as follows: Streptococcus pneumoniae (304 isolates) 0.25 microg/ml, Haemophilus influenzae (135 isolates) 0.125 microg/ ml, Streptococcus pyogenes (66 isolates) 0.25 microg/ml, Moraxella catarrhalis (62 isolates) 0. 25 microg/ml and methicillin-sensitive Staphylococcus aureus (69 isolates) 0.25 microg/ml. These results agreed with reports from other areas. Moxifloxacin showed excellent activity against respiratory pathogens from participant countries.
Cardeñosa G
O
O
Department of Clinical Research, Bayer Latinoamérica, México, DF. oscar.cardenosa.oc1@bayer.es
Soto-Hernández
J L
JL
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D001419:Bacteria / Q000187:drug effects*; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects; D000077266:Moxifloxacin; D011804:Quinolines; D015203:Reproducibility of Results; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013020:South America; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin